Among the novelties that have appeared in recent years in the therapeutic field of immune-mediated inflammatory diseases such as psoriatic arthritis (PsA), rheumatoid arthritis (RA), psoriasis or axial spondyloarthritis (axSpA), the advent of biosimilars of some of the most classic bDMARDs, such as TNFα inhibitors (TNFis), stands out. Here, TNF is linked to psoriatic arthritis.